Myriad Genetics (MYGN) said Monday that it "strongly disagrees" with UnitedHealthcare's decision to restrict coverage access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under the commercial and individual exchange benefit plans.
The updated policy, which takes effect on Jan. 1, is based on the rationale that there is insufficient evidence of efficacy to support coverage of GeneSight, according to the company.
Myriad said it is working with UnitedHealthcare to discuss the clinical evidence for GeneSight and get continued coverage access for the test.
UnitedHealthcare did not immediately respond to MT Newswires' request for comment.
Myriad Genetics' shares were down more than 3% in recent trading.
Price: 17.39, Change: -0.60, Percent Change: -3.34
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。